Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49

Benzinga Newsdesk www.benzinga.com Neutral 51.5%

Neg 0% Neu 51.5% Pos 0%

Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $40 to $49.